Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA‐B) genotype and allopurinol dosing: 2015 update

Yoshiro Saito, L. Dudley Stamp, KE Caudle, MS Hershfield, J. Callaghan, Wichittra Tassaneeyakul, Taisei Mushiroda, Naoyuki Kamatani, BR Goldspiel, EJ Phillips,

Clinical Pharmacology & Therapeutics · 2015 · 157 citations · 4 references

DOIFull text

Open access

Concepts

Abstract

The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B*58:01 Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed the recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplemental Material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).

References

4